Margaret G Woerner
Overview
Explore the profile of Margaret G Woerner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
589
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woerner M, Correll C, Alvir J, Greenwald B, Delman H, Kane J
Neuropsychopharmacology
. 2011 Apr;
36(8):1738-46.
PMID: 21508932
Tardive dyskinesia (TD) rates with second-generation antipsychotics (SGAs) are considered to be low relative to first-generation antipsychotics (FGAs), even in the particularly vulnerable elderly population. However, risk estimates are unavailable...
2.
Goldberg T, Goldman R, Burdick K, Malhotra A, Lencz T, Patel R, et al.
Arch Gen Psychiatry
. 2007 Oct;
64(10):1115-22.
PMID: 17909123
Context: Cognitive impairment in schizophrenia is frequent, involves multiple domains, and is enduring. Numerous recent clinical trials have suggested that second-generation antipsychotic medications significantly enhance cognition in schizophrenia. However, none...
3.
Robinson D, Woerner M, Napolitano B, Patel R, Sevy S, Gunduz-Bruce H, et al.
Am J Psychiatry
. 2006 Dec;
163(12):2096-102.
PMID: 17151160
Objective: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders. Method: One hundred twelve subjects (70% male; mean age=23.3 years [SD =...
4.
Lencz T, Robinson D, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, et al.
Am J Psychiatry
. 2006 Mar;
163(3):529-31.
PMID: 16513877
Objective: All antipsychotics act on the dopamine D(2) receptor. The present study extends prior pharmacogenetic investigations of the D(2) receptor gene (DRD2) by examining, in first-episode schizophrenia patients, promoter region...
5.
Gunduz-Bruce H, McMeniman M, Robinson D, Woerner M, Kane J, Schooler N, et al.
Am J Psychiatry
. 2005 Oct;
162(10):1966-9.
PMID: 16199847
Objective: Duration of untreated psychosis is associated with time to treatment response among patients with schizophrenia. However, individual psychotic symptoms have not been investigated in this context. The authors examined...
6.
Robinson D, Woerner M, Delman H, Kane J
Schizophr Bull
. 2005 Jul;
31(3):705-22.
PMID: 16006592
Studies with first-episode populations offer the unique opportunity to examine the effectiveness and side effects of medications without the confounding effects of prior medication use. This review focuses upon studies...
7.
Saltz B, Robinson D, Woerner M
Prim Care Companion J Clin Psychiatry
. 2005 Jul;
6(Suppl 2):14-9.
PMID: 16001096
Although atypical antipsychotics differ from conventional antipsychotics in their decreased ability to cause reversible drug-induced movement disorders/motor side effects such as dystonia, drug-induced parkinsonism, and akathisia and potentially persistent drug-induced...
8.
Robinson D, Woerner M, McMeniman M, Mendelowitz A, Bilder R
Am J Psychiatry
. 2004 Mar;
161(3):473-9.
PMID: 14992973
Objective: Follow-up studies have found that a substantial number of patients with schizophrenia achieve full recovery (i.e., sustained improvement in both symptoms and social/vocational functioning) when examined decades after an...
9.
Woerner M, Robinson D, Alvir J, Sheitman B, Lieberman J, Kane J
Am J Psychiatry
. 2003 Aug;
160(8):1514-6.
PMID: 12900316
Objective: The authors' goal was to explore whether clozapine given as the first antipsychotic treatment favorably affects the course of schizophrenia. Method: Thirty-four inpatients experiencing their first episode of schizophrenia...
10.
Robinson D, Woerner M, Alvir J, Bilder R, Hinrichsen G, Lieberman J
Schizophr Res
. 2002 Sep;
57(2-3):209-19.
PMID: 12223252
Background: Enhancing medication adherence early in the course of schizophrenia and schizoaffective disorder may substantially improve long-term course. Although extensively studied in multi-episode patients, little data exist on medication adherence...